Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Diabetes Mellitus and Risk of Hepatocellular Carcinoma.

Li X, Wang X, Gao P.

Biomed Res Int. 2017;2017:5202684. doi: 10.1155/2017/5202684. Epub 2017 Dec 12. Review.

2.

Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.

Mills EP, Brown KPD, Smith JD, Vang PW, Trotta K.

Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7. Review.

3.

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Eshraghian A.

World J Gastroenterol. 2017 Nov 14;23(42):7495-7504. doi: 10.3748/wjg.v23.i42.7495.

4.

Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.

Singh S, Osna NA, Kharbanda KK.

World J Gastroenterol. 2017 Sep 28;23(36):6549-6570. doi: 10.3748/wjg.v23.i36.6549. Review.

5.

Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.

Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG.

J Diabetes Complications. 2017 Nov;31(11):1630-1637. doi: 10.1016/j.jdiacomp.2017.07.014. Epub 2017 Jul 31. Review.

PMID:
28886991
6.
7.

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.

Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, Chaiyakunapruk N.

Medicine (Baltimore). 2016 Aug;95(32):e4529. doi: 10.1097/MD.0000000000004529. Review.

8.

A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Temple JL, Cordero P, Li J, Nguyen V, Oben JA.

Int J Mol Sci. 2016 Jun 15;17(6). pii: E947. doi: 10.3390/ijms17060947. Review.

9.

Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.

Kleiner DE, Makhlouf HR.

Clin Liver Dis. 2016 May;20(2):293-312. doi: 10.1016/j.cld.2015.10.011. Epub 2015 Dec 28. Review.

10.

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO).

Obes Facts. 2016;9(2):65-90. doi: 10.1159/000443344. Epub 2016 Apr 8. No abstract available.

11.

Practice patterns in NAFLD and NASH: real life differs from published guidelines.

Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA.

Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581.

12.

Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats.

Linden MA, Lopez KT, Fletcher JA, Morris EM, Meers GM, Siddique S, Laughlin MH, Sowers JR, Thyfault JP, Ibdah JA, Rector RS.

Appl Physiol Nutr Metab. 2015 Oct;40(10):1038-47. doi: 10.1139/apnm-2015-0236. Epub 2015 Jun 24.

13.

Pharmacotherapy for Nonalcoholic Fatty Liver Disease.

Gawrieh S, Chalasani N.

Semin Liver Dis. 2015 Aug;35(3):338-48. doi: 10.1055/s-0035-1562951. Epub 2015 Sep 17. Review.

14.

Systematic review: Preventive and therapeutic applications of metformin in liver disease.

Bhat A, Sebastiani G, Bhat M.

World J Hepatol. 2015 Jun 28;7(12):1652-9. doi: 10.4254/wjh.v7.i12.1652. Review.

15.

Effect of Vitamin E and Metformin on Fatty Liver Disease in Obese Children- Randomized Clinical Trial.

Shiasi Arani K, Taghavi Ardakani A, Moazami Goudarzi R, Talari HR, Hami K, Akbari H, Akbari N.

Iran J Public Health. 2014 Oct;43(10):1417-23.

16.

Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.

Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R.

J Clin Exp Hepatol. 2015 Mar;5(1):51-68. doi: 10.1016/j.jceh.2015.02.006. Epub 2015 Mar 6. Review.

17.

Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome.

Tan S, Vollmar N, Benson S, Sowa JP, Bechmann LP, Gerken G, Fuhrer D, Canbay A.

Int J Endocrinol. 2015;2015:254169. doi: 10.1155/2015/254169. Epub 2015 Mar 19.

18.

Treatment of nonalcoholic steatohepatitis in adults: present and future.

Gitto S, Vitale G, Villa E, Andreone P.

Gastroenterol Res Pract. 2015;2015:732870. doi: 10.1155/2015/732870. Epub 2015 Mar 18. Review.

19.

Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Takahashi Y, Sugimoto K, Inui H, Fukusato T.

World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777. Review.

20.

Nonalcoholic fatty liver disease: new treatments.

Hardy T, Anstee QM, Day CP.

Curr Opin Gastroenterol. 2015 May;31(3):175-83. doi: 10.1097/MOG.0000000000000175. Review.

Supplemental Content

Support Center